CLINICAL TRIALS PROFILE FOR CAPTOPRIL; HYDROCHLOROTHIAZIDE

All Clinical Trials for CAPTOPRIL; HYDROCHLOROTHIAZIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.

Clinical Trial Conditions for CAPTOPRIL; HYDROCHLOROTHIAZIDE

Condition Name

Condition Name for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Intervention	Trials
Hypertension	3
Healthy Volunteers	1

Condition MeSH

Condition MeSH for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Intervention	Trials
Hypertension	3
Pure Autonomic Failure	1

Clinical Trial Locations for CAPTOPRIL; HYDROCHLOROTHIAZIDE

Trials by Country

Trials by Country for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Location	Trials
United States	11
Puerto Rico	1
China	1

Trials by US State

Trials by US State for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Location	Trials
Tennessee	2
Virginia	1
Pennsylvania	1
Ohio	1
Mississippi	1

Clinical Trial Progress for CAPTOPRIL; HYDROCHLOROTHIAZIDE

Clinical Trial Phase

Clinical Trial Phase for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Clinical Trial Phase	Trials
Completed	2
Not yet recruiting	1
Unknown status	1

Clinical Trial Sponsors for CAPTOPRIL; HYDROCHLOROTHIAZIDE

Sponsor Name

Sponsor Name for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Sponsor	Trials
US Department of Veterans Affairs	1
VA Office of Research and Development	1
Vanderbilt University	1

Sponsor Type

Sponsor Type for CAPTOPRIL; HYDROCHLOROTHIAZIDE
Sponsor	Trials
Other	3
U.S. Fed	2
Industry	1

CAPTOPRIL; HYDROCHLOROTHIAZIDE Market Analysis and Financial Projection

Last updated: April 29, 2026

Captopril + Hydrochlorothiazide: What the Clinical Evidence and Market Outlook Say

What is captopril + hydrochlorothiazide and where is it used?

Captopril + hydrochlorothiazide is a fixed-dose combination (FDC) used to treat hypertension. Captopril (an ACE inhibitor) lowers blood pressure by inhibiting angiotensin-converting enzyme; hydrochlorothiazide (a thiazide diuretic) increases sodium and water excretion. The combination targets complementary pathways commonly used in stepped hypertension therapy.

Commercially, the product set is largely generic in most markets. The dominant business question for an R&D or investment view is not whether the combination works, but how it is positioned versus newer branded or device-based strategies, and how pricing and local formularies shape volume.

---

What clinical-trial evidence supports the combination?

Clinical evidence for this ACE inhibitor plus thiazide pairing is long-established in hypertension pharmacology. Trials over multiple decades consistently show that combining an ACE inhibitor with a thiazide diuretic achieves greater blood-pressure reductions than either component alone at tolerated doses.

Core clinical findings (qualitative, class-consistent evidence)

• Additive antihypertensive effect: ACE inhibitor + thiazide regimens produce larger systolic/diastolic reductions than monotherapy.
• Combination tolerability: adverse-event profiles reflect ACE-inhibitor class effects (for example cough, hyperkalemia risk) and thiazide class effects (for example hypokalemia, volume depletion). Clinically, fixed-dose combinations are typically selected to balance efficacy and tolerability.

How these data translate into modern clinical usage

• The combination remains consistent with guideline pathways where patients require multiple drug classes to reach target BP.
• In formularies, the combination is usually treated as a cost-effective option for uncomplicated hypertension rather than a specialty drug.

---

What is the current clinical-trials landscape for captopril + hydrochlorothiazide?

No ongoing global-phase program is typically required for this combination to remain marketed because both components and the combination are mature, and most regulatory frameworks for generics focus on bioequivalence rather than new efficacy trials.

Practical implication for clinical-trial “updates”

• For market-impact purposes, the “trial update” for captopril + hydrochlorothiazide is usually governed by:
  • bioequivalence studies in generic dossiers,
  • labeling updates (safety statements, renal impairment guidance),
  • and periodic pharmacovigilance and post-marketing safety communication rather than new randomized efficacy megatrials.

---

What is the regulatory and labeling baseline?

Labeling content that matters for product risk and commercialization

• Renal function monitoring: ACE inhibitors require creatinine/eGFR monitoring, especially in renal impairment and volume depletion.
• Electrolyte monitoring: the combination can produce both hyperkalemia risk (captopril) and hypokalemia risk (hydrochlorothiazide). Clinical practice focuses on potassium and sodium monitoring.
• ACE-inhibitor class precautions: cough, angioedema risk, contraindications including pregnancy.
• Diuretic class precautions: dehydration risk, electrolyte derangements, and laboratory monitoring.

These are stable, long-standing requirements aligned with ACE inhibitor and thiazide diuretic standards. For business planning, these label elements drive prescriber comfort and monitoring protocols in primary care and internal medicine.

---

How does the competitive landscape shape pricing and uptake?

Market structure

• The combination is predominantly generic.
• Competition is driven by:
  • unit price and payer reimbursement,
  • number of strengths available (dose flexibility affects formulary acceptance),
  • manufacturing reliability and supply continuity,
  • and local regulatory approvals and interchangeability.

Key competitive dynamics

• Formulary preference: many payers prefer low-cost, multiple generics with preferred status based on net price rather than clinical differentiation.
• Switching behavior: once a generic is on formulary, switching is frequent only when a lower-priced alternative wins a contract or when product quality or supply issues arise.
• Dose optimization: fixed-dose products compete on ability to match common titration patterns without requiring multiple separate tablets.

---

What is the market analysis and projection logic for this product class?

A robust projection for an older, generic antihypertensive combination should be modeled around:

1. Hypertension prevalence and treated patient growth (population growth plus improved diagnosis/treatment rates).
2. Generic penetration and price compression (typical post-competition trajectory).
3. Payer procurement behavior (tender cycles and preferred drug lists).
4. Substitution pressure from other generic combinations (ARB/thiazide, ACE inhibitor/diuretic alternatives) and single-pill strategies when payers push adherence.

Base-case market outlook

• Demand should remain supported by chronic hypertension treatment needs.
• Revenue growth is likely limited in most markets due to strong generic price competition.
• Unit volume can be stable or modestly rising where combination therapy remains standard, but revenue growth will depend on tender outcomes and contract pricing.

Downside drivers

• Strong price compression through recurring tenders.
• Shifts toward ARB-based combinations in specific formularies.
• Safety-management scrutiny if monitoring burden leads clinicians to switch regimens.

Upside drivers

• Improved access programs and expansion in primary care.
• Better dose flexibility and packaging that improves adherence and simplifies prescribing.
• Supply stability that prevents lost tenders.

---

Projected market performance (scenario framework)

Because captopril + hydrochlorothiazide is generic, projections are best stated as scenario ranges rather than point estimates. The business levers remain net price, tender outcomes, and competitive substitution.

Scenario	Volume trend	Net price trend	Revenue outcome	Likely drivers
Conservative	Flat to modest decline	Steady to decreasing	Flat to slight decline	Aggressive tender pricing, formulary substitution to ARB/thiazide
Base case	Modest growth	Decreasing but less severe	Low growth or stable	Stable preferred status, controlled competition intensity
Upside	Modest-to-strong growth	Less decline than peers	Moderate growth	Contract wins, strong supply continuity, dose-formulation advantage

---

What commercialization factors matter most for captopril + hydrochlorothiazide?

1) Strength coverage

• Fixed-dose combinations need enough strengths to support titration. Where a manufacturer offers broader strengths, clinicians can keep patients on a single regimen.

2) Supply and tender execution

• In generic antihypertensives, lost supply time often translates directly into lost formulary position.

3) Lab monitoring support

• Pharmacy and clinic workflows can make or break real-world adherence. Products that are easiest to monitor and counsel typically persist on formularies longer.

---

Key Takeaways

• Captopril + hydrochlorothiazide is a mature, class-supported hypertension FDC with long-standing additive efficacy versus monotherapy.
• The “clinical trial update” for this combination is usually dominated by bioequivalence and post-marketing safety maintenance rather than new randomized efficacy breakthroughs.
• Market outlook is driven by chronic hypertension treatment volume, but revenue growth is constrained by generic price compression and payer tender dynamics.
• Projection should be modeled as scenario ranges with net price and formulary position as the primary variables, not by expecting major new efficacy-driven demand shocks.

---

FAQs

1) Is there a current need for large new efficacy trials for captopril + hydrochlorothiazide?
Typically no; generic development and approvals rely on bioequivalence, and efficacy is already established for the ACE inhibitor plus thiazide combination.

2) What monitoring requirements drive real-world prescribing behavior?
Potassium, sodium, and renal function monitoring reflect ACE inhibitor and thiazide risks and can influence switching between combination products.

3) Where does competitive pressure come from?
From low-cost generics in the same class space, especially other ACE inhibitor/diuretic FDCs and ARB/thiazide combinations favored in some formularies.

4) What is the main revenue-risk factor for a generic captopril + hydrochlorothiazide manufacturer?
Tender-driven net price declines and contract loss due to competition.

5) What is the main growth lever for this product?
Formulary retention plus strength coverage and supply continuity that sustain tender competitiveness.

---

References

[1] National Library of Medicine. Captopril and hydrochlorothiazide combination drug label information and safety/usage references. U.S. National Library of Medicine databases.
[2] FDA. Drug Approval and Labeling documents for ACE inhibitors and thiazide diuretics class labeling requirements. U.S. Food and Drug Administration.
[3] World Health Organization. Hypertension fact sheets and treatment framework referencing combination therapy principles. World Health Organization.